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Abstract
Objectives: To assess associations between subcutaneous neurofibromas (SC-NFs) and internal neurofibromas in
patients with neurofibromatosis type 1 (NF-1) and to determine whether the association between SC-NFs and
peripheral neuropathy was ascribable to internal neurofibromas.
Patients and methods: Prospective multicentre case-control study. Between 2005 and 2008, 110 NF-1 adults
having two or more SC-NFs were individually matched for age, sex and hospital with 110 controls who had no SC-
NF. Patients underwent standardized MRI of the spinal cord, nerve roots and sciatic nerves and an
electrophysiological study. Analyses used adjusted multinomial logistic regression (ORa) to estimate the risk of the
presence of internal neurofibromas or peripheral neuropathies associated with patients presented 2 to 9 SC-NFs, at
least 10 SC-NFs as compared to patients without any (referential category).
Results: Cases had a mean age of 41 (± 13) years; 85 (80%) had two to nine SC-NFs and 21 (19%) at least ten SC-
NFs. SC-NFs were more strongly associated with internal neurofibromas in patients with ten or more SC-NFs than
in patients with fewer NF-SCs (e.g., sciatic nerve, aOR = 29.1 [8.5 to 100] vs. 4.3 [2.1 to 9.0]). The association with
SC-NFs was stronger for diffuse, intradural, and > 3 cm internal neurofibromas than with other internal
neurofibromas. Axonal neuropathy with slowed conduction velocities (SCV) was more strongly associated with
having at least ten SC-NFs (aOR = 29.9, 5.5 to 162.3) than with having fewer SC-NFs (aOR = 4.4, 0.9 to 22.0).
Bivariate analyses showed that the association between axonal neuropathy with SCV and sciatic neurofibromas was
mediated by the association between SC-NFs and sciatic neurofibromas.
Conclusion: The at-risk phenotype of NF-1 patients (i.e. NF-1 patients with SC-NFs) is ascribable to associations
linking SC-NFs to internal neurofibromas at risk for malignant transformation and to axonal neuropathies with
slowed conduction velocities. Axonal neuropathies with SCV are particularly common in patients with at least ten
SC-NFs.
Registration details: ORPHA86301
Introduction
Neurofibromatosis type 1 (NF-1 [MIM 162200]) is a
common autosomal dominant disorder associated with
increased morbidity and mortality[1]. Neurofibromas are
the hallmark of NF1. They are benign tumors that arise
from connective tissue of nerve sheaths, especially the
endoneurium. We used the classification proposed by
Riccardi which defines four categories of neurofibromas
[2]: (i) cutaneous neurofibromas, presenting as an exo-
phytoc tumor moving with the skin on examination, (ii)
subcutaneous neurofibromas that lie deeper in the skin,
do not move with it, are firm to palpation and may be
tender (iii) internal or deep neurofibromas may involve
any nerve anywhere along its length and are not pal-
pated. They are therefore identified later in their course
of growth (iv) plexiform neurofibromas may involve
multiple fascicles and branches, and extend into
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thickened hypertrophic skin, hyperpigmentation of tis-
sue and subcutaneous tumor [2,3].
Subcutaneous neurofibromas (SC-NFs) were indepen-
dently associated with mortality among adults with NF-
1 in two independent populations from France [4] and
North America [5]. The main causes of death were
spinal cord compression by internal neurofibromas and
malignant peripheral nerve-sheath tumours (MPNSTs)
developed from pre-existing internal neurofibromas
[4,5]. A recent study demonstrated that having at least
two SC-NFs was independently associated with having
internal neurofibromas [6]. However, this association
needs to be characterised in detail. Furthermore, a
strong association between peripheral neuropathy and
SC-NFs has been reported [7]. We hypothesized that
this association was related to an association between
SC-NFs and internal neurofibromas located along the
nerve roots.
The primary objective of this prospective matched
case-control study was to characterise the association
between SC-NFs and internal neurofibromas in patients
routinely investigated with magnetic resonance imaging
(MRI), the most sensitive method for detecting internal
neurofibromas and assessing their features (e.g., type,
distribution, location, and size). The secondary objective
was to determine whether peripheral neuropathy was
associated with having internal neurofibromas along the
nerve roots. Peripheral neuropathy was detected using a
routine electrophysiological study.
Patients And Methods
Study design
This case-control study was conducted prospectively
from February 2005 to December 2008 in three hospital
centres in France. For a type 1 error of 0.05, 100 cases
and 100 controls provided 90% power for detecting
odds ratios (ORs) greater than 3 for factors having a
20% prevalence in the general population of adults with
NF-1. We decided to select 110 cases and 110 controls
to allow for some patients being excluded secondarily
(e.g., because of contraindications to MRI). Controls
were matched individually to cases on age (± 3 years),
sex, and hospital. The study was approved by the Ile-de-
France IX (Paris, France) ethics committee, and all cases
and controls gave their informed consent.
Cases
The cases were identified among adults with NF-1 in
our NF-network database. They met diagnostic criteria
for NF-1 established at the National Institutes of Health
Consensus Development Conference (n = 1 099) [8].
Among patients aged 17 years or older (n = 748), we
included probands and patients with sporadic disease (n
= 515) who had at least two SC-NFs (n = 192), defined
as palpable nodules along peripheral nerves under the
skin. We did not include patients having less than two
SC-NFs (n = 259), pregnant women, and patients with
contraindications to MRI (e.g., cardiac pacemaker, ferro-
magnetic or electronically operated stapedial implant,
haemostatic clip, or metallic splinters) (n = 64).
Among these 192 potential cases, 110 cases were
selected at random for study inclusion.
Controls
For each case, we looked for a control individually
matched on age, sex, and centre in the NF-network
database. Potential controls were probands or sporadic
NF-1 patients who were at least 17 years old and had
no SC-NFs and no contraindications to MRI. When we
found several controls appropriate for the same case, we
selected one at random. Thus, 110 controls were
selected.
Data collection
Data, including demographic information (age, sex and
body mass index) and clinical features were collected
during routine clinical assessments at the neurofibroma-
tosis clinics by one dermatologist at each centre (SF,
PC, SB) (Table 1). The skin lesions were described in
detail: number of café-au-lait spots, cutaneous neurofi-
bromas (0, 1, 2-9, 10-99, ≥100), and SC-NFs (0, 2-9, 10-
99, ≥100); and count and location of plexiform neurofi-
bromas defined as benign peripheral nerve-sheath
tumours involving multiple nerve fascicles or branches
Table 1 Characteristics of adults with at least two
subcutaneous neurofibromas (cases) and controls
Clinical features Cases n =
106
Controls n =
102
p
value*
Matching variables
Female gender 62 (59) 62 (61)
Age (years) 41 (± 13) 41 (± 14)
Clinical variables
Familial case 56 (47) 56 (45) 0.76
No cutaneous neurofibromas 13 (12) 4 (4) 0.03
Plexiform neurofibromas 66 (62) 49 (48) 0.04
Large café-au-lait spots
(number)
8.6 (± 4.8) 10.1 (± 10.1) 0.07
No freckles 21 (20) 12 (12) 0.11
Lisch nodules 48 (81) 45 (80) 0.89
Scoliosis 46 (43) 42 (41) 0.75
Headache 38 (36) 41 (40) 0.52
Epilepsy 2 (2) 2 (2) 0.97
Learning disabilities 58 (57) 52 (49) 0.26
*p value obtained using chi-square test or Fisher exact or non-parametric
Kruskal-Wallis test as appropriate
Data are numbers (%) or means ± 1 standard deviation
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rofibromas were cutaneous or subcutaneous and were
identified clinically. Other items were coded as present
or absent. Orthopaedic complications (scoliosis), neuro-
logical abnormalities (headache, epilepsy, learning dis-
abilities), and endocrinological disorders (hypertension)
were also recorded.
Identification and characterisation of internal
neurofibromas
All cases and controls had a standardized MRI study of
the spinal cord, nerve roots, and sciatic nerve. MRI was
performed using a field strength of 1.5-T. T1- and T2-
weighted nonenhanced sequences (coronal plane)
including short-tau inversion-recovery (STIR) sequences
were acquired using a slice thickness of 4 mm with no
gap. The image matrix was 512/256. Three coronal
images (cervico-thoracic spine, thoraco-lumbo-sacral
spine, and pelvis/thighs) were acquired to characterize
the internal neurofibromas. MRI data were reviewed by
a senior radiologist (PB) who was unaware of the clinical
features. We recorded the presence of internal neurofi-
bromas, their type (along the spinal cord or sciatic
nerve roots), their distribution (focal or diffuse), their
size (< 3 cm or ≥3 cm), and their location (intradural or
extradural).
Electrophysiological study
All cases and controls underwent a standardized electro-
physiological study to look for peripheral neuropathy.
The investigation included sensory/motor nerve conduc-
tion study for the superficial/deep peroneal nerves and
the sural/tibial nerves at both lower limbs and for the
median and ulnar nerves at one upper limb. The elec-
trophysiological data were reviewed by a senior physiol-
ogist (JPL) who was unaware of the clinical features.
Patients were classified as having either no neuropathy
(normal nerve conduction study) or an axonal distal,
sensory-predominant polyneuropathy (characterized by a
bilateral and symmetric reduction of sensory nerve
action potential amplitude at the lower limbs with less
marked abnormalities regarding motor nerve conduction
parameters and upper limb results). Among axonal neu-
ropathies, we differentiated those with and without slo-
wed conduction velocities (SCVs). Neuropathies with
and without SCVs shared the same presentation in
terms of action potential amplitude reduction, but neu-
ropathies with SCVs additionally showed moderate but
diffuse decrease of motor nerve conductions, very
homogeneously, without any increased temporal disper-
sion or conduction block. Therefore, we assumed that
neuropathies with SCVs were primarily axonal because
they did not present any relevant criteria in favour of a
demyelinating process [9]. We also determined the pre-
sence of proximal/nerve root involvement ("radiculopa-
thy”) according to a selective alteration (absence or
prolonged latency) of the F-waves and H-reflexes at the
lower limbs.
Statistical analysis
Data were double-keyboarded and analysed using
STATA software version 11 (Stata Corporation, College
Station, TX, USA). All tests were two-tailed and p
values < 0.05 were considered statistically significant.
Quantitative variables are reported as mean ± standard
deviation (SD) and qualitative variables as number (%).
First, we compared cases and controls using univariate
analysis (chi-square test or Fisher exact test as appropri-
ate). Then, logistic regression models were used to esti-
mate ORs adjusted for matching variables (aORs) with
their 95% confidence intervals (95%CIs) for each charac-
teristic of internal neurofibromas (spinal cord or sciatic
nerve root, intra or extradural, diffuse or focal, size, and
size category < 3 cm or ≥3 cm). Similarly, we estimated
aORs with their 95%CIs separately for each type of per-
ipheral neuropathy and radiculopathy. Then, to test our
hypothesis that the association between SC-NFs and per-
ipheral neuropathy was related to internal neurofibromas
along the nerve roots, bivariate analyses including periph-
eral neuropathies and internal neurofibromas were per-
formed. Finally, to assess whether the number of SC-NFs
was associated with internal neurofibromas and/or per-
ipheral neuropathy, cases were classified into two groups
based on whether they had two to nine SC-NFs or at
least ten SC-NFs. The, risk associated with each of these
categories versus the controls (no SC-NFs) was estimated
using adjusted multinomial logistic regression (aOR).
Control patients were the referential category.
Results
Between 2005 and 2008, 110 cases were matched for
age, sex, and hospital to 110 NF-1 controls. Four cases
and eight controls were excluded secondarily because
their MRI scans were not interpretable. Table 1 reports
the characteristics of the 106 cases and 102 controls.
The cases had a mean age of 41 (± 13) years; 59% were
females, 85 (80%) had two to nine SC-NFs and 21 (19%)
at least ten SC-NFs. There were no significant differ-
ences between cases and controls for age and sex
(matching variables) or clinical features (e.g., dermatolo-
gical characteristics, orthopaedic complications, and
neurological abnormalities) except the cutaneous and
plexiform neurofibromas. Significantly greater propor-
tions of cases than controls had no cutaneous neurofi-
bromas (p =0 . 0 3 )a n da tl e a s to n ep l e x i f o r m
neurofibroma (p = 0.04). Cases had fewer large café-au-
lait spots compared to controls but the difference was
not statistically significant (p = 0.07).
Table 2 summarises the results of the univariate analy-
sis. The presence of SC-NFs was strongly associated
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2.2 to 8.2) and sciatic neurofibromas (aOR, 6.1; 95%CI,
2.9 to 13). The associations tended to be stronger for
diffuse vs. focal paraspinal neurofibromas, intradural vs.
extradural neurofibromas, and internal neurofibromas
measuring at least 3 cm vs. less than 3 cm. Similarly, for
sciatic neurofibromas, diffuse distribution and tumour
size of at least 3 cm showed trends toward stronger
associations with SC-NFs than focal distribution and
size smaller than 3 cm, respectively. Finally, the pre-
sence of axonal neuropathy with SCVs was significantly
associated with having SC-NFs (aOR, 7.7; 95%CI, 1.6 to
36.6) (Table 3).
Radiculopathies were not significantly associated with
the presence of SC-NFs (Table 3).
The joint analysis identified no interactions between
variables associated with the presence of SC-NFs. A
strong association was found between the presence of
sciatic neurofibromas and that of axonal neuropathy with
SCVs (aOR = 22.1; 95% CI, 4.2 to 115.3). In the bivariate
analysis including axonal neuropathy with SCVs and scia-
tic neurofibromas, axonal neuropathy with SCVs was no
longer associated with SC-NFs (aOR, 3.0; 95%CI, 0.6 to
15.1; p = 0.18). The association between axonal neuropa-
thy with SCVs and SC-NFs persisted only in the sub-
group with sciatic neurofibromas (aOR, 2.00; 95%CI, 1.01
to 4.12; vs. aOR, 0.69; 95%CI, 0.24 to 4.12 in the sub-
group without sciatic neurofibromas). Thus, the associa-
tion between SC-NF and axonal neuropathy with SCVs
was due to the presence of internal sciatic neurofibromas.
Table 2 Presence of internal neurofibromas in cases and controls
Cases, n = 106 (%) Controls, n = 102 (%) Odds Ratio* (95%CI) p value**
Paraspinal neurofibromas 54 (51) 20 (20) 4.3 (2.2 - 8.2) < 10
-4
Distribution
None 52 (49) 82 (81) 1
Focal 26 (25) 16 (15) 2.6 (1.2 - 5.3)
Diffuse 28 (26) 4 (4) 14.7 (3.8 - 57.3) < 10
-4
Location
None 52 (49) 82 (81) 1
Extradural 37 (35) 17 (16) 3.2 (1.6 - 6.4)
Intradural 17 (16) 3 (3) 8.8 (2.3 - 33.9) < 10
-4
Size
None 52 (49) 82 (81) 1
< 3 cm 30 (28) 14 (14) 3.4 (1.6 - 7.2)
≥3 cm 24 (23) 6 (5) 6.3 (2.3 - 17.4) < 10
-4
Sciatic neurofibromas 50 (47) 13(13) 6.1 (2.9 - 13.0) < 10
-4
Distribution
None 63 (60) 90 (88) 1
Focal 15 (14) 9 (9) 2.7 (1.1 - 6.8)
Diffuse 28 (26) 3 (3) 15.4 (4.0 - 59.7) < 10
-4
Size
None 56 (53) 89 (88) 1
< 3 cm 33 (31) 9 (9) 5.8 (2.5 - 13.8)
≥3 cm 17 (16) 4 (4) 6.8 (2.1 - 22.2) < 10
-4
* Odds ratio with 95% confidence interval (95% CI) by logistic regression adjusted for matching variables (age, sex, hospital)
**p value from logistic regression
Table 3 Presence of peripheral neuropathies in cases and controls
Cases n = 106 (%) Controls n = 102 (%) Odds Ratio* (95%CI) p (chi
2)
Peripheral Neuropathies
none 85 (80) 94 (92) 1 0.009
axonal 7 (7) 6 (6) 1.3 (0.4 - 4.0)
axonal with SCVs** 14 (13) 2 (2) 7.7 (1.6 - 36.6)
Radiculopathies 24 (23) 14 (14) 1.8 (0.9 - 3.8) 0.09
*Odds ratio with 95% confidence interval (95% CI) by logistic regression adjusted for matching variables (age, sex, hospital)
** slowed conduction velocities
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with at least ten SC-NFs had a significantly higher risk
of paraspinal neurofibromas (aOR, 82; 95%CI, 10.4 to
647.9) compared to patients with two to nine SC-NFs
(aOR, 2.7; 95%CI, 1.4 to 5.3) (Figure 1). This dose-effect
relationship was observed for distribution, location, and
size (Figure 1, Table 4). Similar dose-effect relationships
were found for sciatic neurofibromas, particularly
regarding distribution, location, size (Figure 1, Table 4).
Finally, axonal neuropathies with SCVs were more com-
m o ni np a t i e n t sw i t ha tl e a s tt e nS C - N F s( a O R ,2 9 . 9 ;
95%CI, 5.5 to 162.3) than in patients with two to nine
SC-NFs (aOR, 4.4; 95%CI, 0.9 to 22.0) (Figure 1).
Discussion
This study shows that sub-cutaneous neurofibromas
were significantly associated with having paraspinal and
sciatic neurofibromas detected by routine MRI. The
strength of the association tended to be higher when the
paraspinal and sciatic neurofibromas were diffuse, intra-
dural, and at least 3 cm in diameter. Moreover, para-
spinal and sciatic neurofibromas were significantly more
common in patients having at least ten SC-NFs than in
patients having two to nine SC-NFs. A dose-effect rela-
tionship was also found for distribution, location, and
size of the internal neurofibromas. Finally, our data indi-
cate that the strong association between SC-NFs and
axonal neuropathy with SCVs is due to the association
between SC-NFs and internal neurofibromas.
Neurofibromatosis-1 (NF1) is a common disease with
an increased propensity for developing both benign and
malignant tumors [10]. NF1 has been reported to be
associated with a 15-year decrease in life expectancy [1].
One of the aims of the Réseau NF-France was to iden-
tify clinical predictive factors for mortality, in order to
better adjust the follow up and propose new treatments
for eligible patients. We previously demonstrated in two
different NF1 populations, from France [4] and North
America [5], that the presence of at least 2 subcuta-
neous neurofibromas was associated with a higher risk
of death. The main causes of death were compression of
neighboring organs due to internal neurofibromas, and
malignant peripheral nerve-sheath tumours developing
from preexisting internal neurofibromas.
The main concern in the long-term clinical manage-
ment of adults with NF-1 is the identification of patients
at high risk for MPNSTs developed from pre-existing
internal neurofibromas. At present, no effective treat-
ment is available for MPNST untreatable by surgery.
New treatments are usually approved based on proof of
efficacy in a controlled trial. When conducting con-
trolled trials, an important consideration is patient selec-
tion based on severity of illness. Controlled trials in
adults with NF-1 should target patients who have a
Figure 1 Odds ratios (ORs) with their 95% confidence intervals for several types of internal neurofibromas and peripheral
neuropathies in patients with two to nine subcutaneous neurofibromas (SC-NFs) or at least ten SC-NFs. The ORs associated with each
type of internal neurofibroma and peripheral neuropathy were estimated using multinomial logistic regression adjusted for the matching
variables (age, sex, and centre), using the control group of patients with neurofibromatosis type 1 and no SC-NFs (n = 102) as the reference
category. ORs were log-transformed.
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Patients with a high risk of internal neurofibromas must
be therefore identified as potential new therapies are
being developed. For instance, there are at least seven
phase II/III trials in which the internal neurofibromas
are being treated by targeted therapy such as ranibizu-
mab, niltotinib... (clinicaltrials.gov). In addition, we
believe that targeted therapy will be of greater efficacy
on non-transformed internal neurofibromas. At present
time, an annual careful clinical examination is recom-
mended for all patients with NF1 in order to detect clin-
ical symptoms associated with MPNSTs such as pain,
neurological deficit and enlargement of a pre-existing
peripheral nerve sheath tumour [11]. Routine MRI
screening, which is highly reliable for detecting internal
neurofibromas, is not recommended in patients without
the alarming clinical signs mentioned above [12]. It is
therefore critical to precisely clinically identify the
patients with the maximum likelihood of having internal
neurofibromas and to closely follow them by it iterating
MRI. The first step is to assess recognizable clinical fea-
tures as potential predictors of morbidity and mortality
in order to further improve the clinical management of
NF1. We recently developed a clinical score for predict-
ing the presence of internal neurofibromas in adults
with NF1. The NF1Score, computed via a linear combi-
nation of four variables (age ≤ 30 years, fewer than six
café-au-lait spots, no cutaneous neurofibromas, and two
or more SC-NFs), can be used to accurately predict the
presence of internal neurofibromas in NF-1 patients and
help target patients for now emerging clinical trial [6].
The high point scoring of the NF1Score is the presence
of SC-NFs. SC-NFs were highly associated with having
internal neurofibromas (OR,4 . 7 ;9 5 % C I ,2 . 1 - 1 0 . 5 )[ 6 ] .
The second step, our present work, was to confirm and
explain a detailed and unbiased characterisation of the
links between internal neurofibromas and SC-NFs. To
our knowledge, this was the first controlled study invol-
ving a detailed characterization of the relationship
between SC-NFs, internal neurofibromas, and peripheral
neuropathies in adults with NF-1.
The internal validity of this study depends on many
factors, including the unbiased recruitment of cases and
controls and the accuracy of the information obtained
about the presence of internal neurofibromas. MRI, an
extremely reliable method for detecting internal
Table 4 Association between subcutaneous neurofibromas (SC-NFs) and several types of internal neurofibromas and
peripheral neurofibromas
No SC-NFs (n = 102) Controls 2-9 SC-NFs (n = 85) OR** (95%CI) ≥10 SC-NFs (n = 21) OR** (95%CI)
Paraspinal neurofibromas 1 2.7 (1.4 - 5.3) 82 (10.4 - 647.9)
Distribution
None - 1 1
Focal 1 2.4 (1.2 - 5.0) 10.3 (0.9 - 120.0)
Diffuse 1 5.4 (1.4 - 20.4) 492.0 (48.4 - 5006.2)
Location
None - 1 1
Intradural 1 3.7 (0.9 - 15.0) 1270.0 (25.6 - 2849.8)
Extradural 1 2.4 (1.2 - 4.8) 45.0 (5.4 - 374.2)
Size
None - 1 1
< 3 cm 1 2.3 (1.1 - 4.9) 58.6 (6.9 - 494.0)
≥3 cm 1 3.8 (1.4 - 10.4) 136.7 (14.9 - 1253.9)
Sciatic neurofibromas 1 4.3 (2.1 - 9.0) 29.1 (8.5 - 100.0)
Distribution
None - 1 1
Focal 1 2.9 (1.2 - 7.0) -
Diffuse 1 5.7 (1.5 - 21.7) 266.8 (41.6 - 1712.7)
Size
None - 1 1
< 3 cm 1 4.2 (1.8 - 9.8) 27.2 (7.2 - 103.2)
≥3 cm 1 4.7 (1.4 - 15.5) 33.4 (6.6 - 167.6)
Neuropathies with SCV*** 1 4.4 (0.9 - 22) 29.9 (5.5 - 162.3)
*Reference category
**Odds ratio with 95% confidence interval (95%CI) by multinomial logistic regression adjusted for matching variables (age, sex, hospital), using the control group
of patients with neurofibromatosis type 1 and no SC-NFs (n = 102) as the reference category.
*** Slowed conduction velocities
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and controls. Assessment bias was minimized by having
the MRI data reviewed by senior radiologist (PB) who
was unaware of the clinical data. Assessment bias was
minimized by having the electrophysiological data
reviewed by senior physiologist (JPL) who was unaware
of the MRI data. Clinical information regarding the neu-
ropathy was not available. However, according to our
experience the diffuse symmetric peripheral neuropa-
thies related to NF-1 are asymptomatic or pauci-symp-
tomatic with minor sensory manifestations [7].
As with all hospital-based case-control studies, selec-
tion bias cannot be excluded. However, the prevalence
of the various clinical features in the cases were similar
to those in the controls (except for the number of cuta-
neous neurofibromas) and to those reported previously
in NF-1 patients, indicating that our study population
was representative of NF-1 patients [13]. Regarding the
number of cutaneous neurofibromas, the association
linking the absence of cutaneous neurofibromas to the
presence of SC-NF is in agreement with a previous
study showing higher mortality among NF-1 patients
who had no cutaneous neurofibromas [4].
In summary, this study shows a strong association
between the presence of internal neurofibromas and
the presence of SC-NF. The increased risk in NF-1
patients with subcutaneous neurofibromas (high risk
phenotype) can be ascribed in part to the associations
between SC-NFs and internal neurofibromas (prone to
transformation to MPNSTs) and the presence of a
neuropathy with SCVs. The prevalence of neuropathy
with SCVs is particularly high in patients with at least
ten SC-NFs. To better understand the patho-physiolo-
gical processes in the high risk phenotype of NF-1
patients, the next step would be to perform genotype-
p h e n o t y p ec o r r e l a t i o ns t u d i e s .Am o r es e v e r ec l i n i c a l
phenotype has been reported in NF1 patients carrying
genomic microdeletions involving NF1 and surround-
ing gene compare to patients with mutations restricted
to the NF1 genes. A recent study confirmed in a large
cohort that NF1 microdeletion patients have a signifi-
cantly higher incidence of learning disabilities and
facial dysmorphism than patients with intragenic NF1
mutation [14]. However no association were found
between SC-NFs and MPNSTs and NF1 microdeletion
patients.
Further studies are therefore needed to find others
genes beside NF1 implied in the internal NF develop-
ment. One of the major aims of such studies would be
to identify key targets for novel drugs’ development.
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